使用脑脊液 Aβ（Aβ）42/40 比值诊断阿尔茨海默病的优缺点。
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.
机构信息
Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Memory Clinic, Skåne University Hospital, Malmö, Sweden.
出版信息
Alzheimers Res Ther. 2019 Apr 22;11(1):34. doi: 10.1186/s13195-019-0485-0.
Abstract
The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer's Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of dementia (non-AD). The concentration ratio of Aβ to Aβ (Aβ Ratio) has been suggested to be superior to the concentration of Aβ alone when identifying patients with AD. This article reviews the available evidence on the use of the CSF Aβ ratio in the diagnosis of AD. Based on the body of evidence presented herein, it is the conclusion of the current working group that the CSF Aβ ratio, rather than the absolute value of CSF Aβ, should be used when analysing CSF AD biomarkers to improve the percentage of appropriately diagnosed patients.
摘要
脑脊液（CSF）生化标志物（生物标志物）β淀粉样蛋白 42（Aβ）、总 Tau（T-tau）和 Tau 磷酸化在苏氨酸 181 位（P-tau）已被证明对因阿尔茨海默病（AD）导致的轻度认知障碍和痴呆具有诊断准确性。为了提高 AD 诊断的准确性，能够区分 AD 和其他类型的痴呆症（非 AD）非常重要。当识别 AD 患者时，Aβ 与 Aβ 的浓度比（Aβ 比值）已被证明优于 Aβ 的浓度。本文回顾了 CSF Aβ 比值在 AD 诊断中的应用的现有证据。基于本文提出的证据，当前工作组的结论是，在分析 CSF AD 生物标志物时，应使用 CSF Aβ 比值而不是 CSF Aβ 的绝对值，以提高适当诊断患者的比例。
相似文献
1
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.
Alzheimers Res Ther. 2019 Apr 22;11(1):34. doi: 10.1186/s13195-019-0485-0.
2
Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
J Alzheimers Dis. 2014;41(2):377-86. doi: 10.3233/JAD-131838.
3
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725.
4
Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
J Alzheimers Dis. 2016;51(4):1069-83. doi: 10.3233/JAD-150731.
5
The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
Curr Alzheimer Res. 2010 Aug;7(5):470-6. doi: 10.2174/156720510791383796.
6
Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
Alzheimers Res Ther. 2018 Mar 20;10(1):33. doi: 10.1186/s13195-018-0362-2.
7
The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease.
Clin Chim Acta. 2019 Jul;494:71-73. doi: 10.1016/j.cca.2019.03.001. Epub 2019 Mar 4.
8
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.
9
The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "In Vivo" in the Differential Diagnosis of Alzheimer's Dementia.
Curr Alzheimer Res. 2019;16(7):587-595. doi: 10.2174/1567205016666190725150836.
10
CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):160-4. doi: 10.1136/jnnp.2009.199398. Epub 2010 Nov 3.
引用本文的文献
1
Synthesis and characterization of miniaturized aptamer-based monolithic sorbent for selective extraction of β-amyloid peptides from cerebrospinal fluid.
Anal Bioanal Chem. 2025 Sep 1. doi: 10.1007/s00216-025-06085-7.
2
Integrating neuroinflammation biomarkers into the ATN(X) framework: Advances in Alzheimer's pathogenesis, diagnosis, and insights from non-human primate models.
Alzheimers Dement. 2025 Aug;21(8):e70472. doi: 10.1002/alz.70472.
3
Potential Role of Lymphovenous Bypass in Mitigating Alzheimer's Disease Dementia.
Arch Plast Surg. 2025 Jul 23;52(4):247-252. doi: 10.1055/a-2627-9243. eCollection 2025 Jul.
4
Practical Guide of the Korean Association for Geriatric Psychiatry to Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: Focused on Lecanemab.
J Korean Med Sci. 2025 Jul 21;40(28):e215. doi: 10.3346/jkms.2025.40.e215.
5
Predicting diagnostic conversion from mild cognitive impairment to Alzheimer's disease: A Bayesian hierarchical model approach using ADNI patient data.
J Alzheimers Dis. 2025 Jul 20;107(1):13872877251360228. doi: 10.1177/13872877251360228.
6
CSF Amyloid-β42 associates with neuropsychiatric and cognitive outcomes via cerebral glucose metabolism.
Mol Brain. 2025 Jul 1;18(1):55. doi: 10.1186/s13041-025-01229-3.
7
Physics of Protein Aggregation in Normal and Accelerated Brain Aging.
Bioessays. 2025 Aug;47(8):e70030. doi: 10.1002/bies.70030. Epub 2025 Jun 20.
8
Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosis.
EBioMedicine. 2025 Jun 12;117:105805. doi: 10.1016/j.ebiom.2025.105805.
9
2D-QSAR and molecular docking based virtual screening and molecular dynamic simulation of the indole based herbal molecules for the discovery of potent molecules in the treatment of Alzheimer's disease.
In Silico Pharmacol. 2025 Jun 7;13(2):81. doi: 10.1007/s40203-025-00364-y. eCollection 2025.
10
Fabrication of MIP-based sensors for femtomolar detection of kynurenic acid for early diagnosis of neurodegenerative diseases.
ACS Omega. 2025 May 16;10(20):20907-20921. doi: 10.1021/acsomega.5c02339. eCollection 2025 May 27.
本文引用的文献
1
Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM Scale.
Front Aging Neurosci. 2018 May 28;10:138. doi: 10.3389/fnagi.2018.00138. eCollection 2018.
2
Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
Alzheimers Res Ther. 2018 Mar 20;10(1):33. doi: 10.1186/s13195-018-0362-2.
3
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.
Alzheimers Dement. 2018 Nov;14(11):1460-1469. doi: 10.1016/j.jalz.2018.01.013. Epub 2018 Mar 2.
4
Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
JAMA Neurol. 2017 Dec 1;74(12):1492-1501. doi: 10.1001/jamaneurol.2017.2814.
5
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.
World J Biol Psychiatry. 2018 Jun;19(4):244-328. doi: 10.1080/15622975.2017.1375556. Epub 2017 Oct 27.
6
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Alzheimers Res Ther. 2017 Oct 10;9(1):84. doi: 10.1186/s13195-017-0301-7.
7
Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.
J Alzheimers Dis. 2017;57(2):437-445. doi: 10.3233/JAD-160865.
8
How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ/Aβ ratio.
Alzheimers Dement. 2017 Aug;13(8):885-892. doi: 10.1016/j.jalz.2017.01.010. Epub 2017 Feb 21.
9
Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
J Alzheimers Dis. 2017;55(2):813-822. doi: 10.3233/JAD-160722.
10
Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.
Brain. 2016 Sep;139(Pt 9):2540-53. doi: 10.1093/brain/aww160. Epub 2016 Jul 7.
Zotero 插件